Evidence map›Paper›PMID 33717563›Full record

ArticleJournal of thoracic disease2021

How the COVID-19 pandemic changed treatment of severe aortic stenosis: a single cardiac center experience.

Bartlomiej Perek, Anna Olasinska-Wisniewska, Marcin Misterski, Mateusz Puslecki, Marek Grygier, Piotr Buczkowski, Maciej Lesiak, Tomasz Stankowski, Lukasz Szarpak, Kurt Ruetzler and 2 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of thoracic disease, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Bartlomiej PerekDepartment of Cardiac Surgery and Transplantology, Poznan University of Medical Sciences, Poznan, Poland.
Anna Olasinska-WisniewskaDepartment of Cardiac Surgery and Transplantology, Poznan University of Medical Sciences, Poznan, Poland.
Marcin MisterskiDepartment of Cardiac Surgery and Transplantology, Poznan University of Medical Sciences, Poznan, Poland.
Mateusz PusleckiDepartment of Cardiac Surgery and Transplantology, Poznan University of Medical Sciences, Poznan, Poland.
Marek Grygier1st Department of Cardiology, Poznan University of Medical Sciences, Poznan, Poland.
Piotr BuczkowskiDepartment of Cardiac Surgery and Transplantology, Poznan University of Medical Sciences, Poznan, Poland.
Maciej Lesiak1st Department of Cardiology, Poznan University of Medical Sciences, Poznan, Poland.
Tomasz StankowskiDepartment of Cardiac Surgery, Sana-Herzzentrum Cottbus, Cottbus, Germany.
Lukasz SzarpakBialystok Oncology Center, Bialystok, Poland.
Kurt RuetzlerDepartment of Outcomes Research, Anesthesiology Institute, Cleveland Clinic, OH, USA.
Oguz TuranDepartment of Outcomes Research, Anesthesiology Institute, Cleveland Clinic, OH, USA.
Marek JemielityDepartment of Cardiac Surgery and Transplantology, Poznan University of Medical Sciences, Poznan, Poland.
Poznan University of Medical Sciences · PLOutcomes Research Consortium · USUczelnia Warszawska im. Marii Skłodowskiej-Curie · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCurrently, two effective therapeutic options for severe aortic stenosis (AS) are available, one catheter-based [transcatheter aortic valve implantation (TAVI)], the other open surgical approach [surgical aortic valve replacement (SAVR)]. The COVID-19 pandemic has limited the availability of medical procedures. The purpose of this cross-sectional study was to assess if this pandemic had any impact on the treatment strategy of severe AS in a single cardiac center.

methodsThis study involved AS patients treated in 3-month periods (February through April) over 3 consecutive years 2018, 2019 [defined as COV(-) group] and 2020 [COV(+)]. We assessed if there were any differences regarding patients' clinical profile, applied therapeutic method, procedure complexity and early clinical outcomes.

resultsIn the years 2018 through 2019, approximately 50% of AS patients were treated classically (SAVR) while in 2020 this rate dropped to 34%. The preoperative clinical characteristic of TAVI subjects was comparable irrespective of the year. Regarding SAVR, more patients in COV(+) underwent urgent and more complex procedures. More of them were found in NYHA class III or IV, and had lower left ventricular ejection fraction (LVEF) (51.9%±14.4%

conclusionsThe coronavirus pandemic has changed substantially the management of severe AS. The shift into less invasive treatment method of AS patients resulted in shortening of in-hospital stay without compromise of short-term outcomes.

Indexed as

Aortic stenosis (AS)aortic valve replacementCOVID-19 pandemictranscatheter aortic valve implantation (TAVI)

Identifiers

PMID33717563
PMCPMC7947507
OpenAlexW3120537135

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.